What is the evidence supporting the treatment of people with diabetes and CKD G3 G4, A3 with RASi?
There is strong evidence supporting the treatment of people with diabetes and CKD G3 G4, A3 with RASi due to their renoprotective effects. In a meta-analysis performed by the ERT, ACEi compared to placebo or standard of care was found to reduce the risk of doubling of serum creatinine by 30% (RR: 0.70; 95% CI: 0.54-0.90) with a mean follow-up of 32 months and an absolute difference was not statistically significant. Additionally, ACEi was found to reduce albuminuria in the CKD population with diabetes.